Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > From Bill & Melinda Gates Foundation .......

<< Previous

Bullboard Posts

Next >>

Comment by bligickaon Jan 03, 2021 10:05am

108 Views

Post# 32211176

RE:RE:From Bill & Melinda Gates Foundation .......

I wonder if Bill has called David or vice versa.......I'm sure Vaxil is under Gates Foundation radar !!!

bligicka wrote: Now that David has confirmed the companies direction moving forward on his latest video its safe to say funding from Bill Gates will come....

Vaxil meets all the Gates Foundation requirements for funding .....

A inexpensive oral vaccine is a game changer for Africa and Latin America .......

I expect things will start to move quickly for Vaxil this year !!!

bligicka wrote:
In fact, this announcement brings the Gates Foundation’s total contribution towards fighting the pandemic to $1.75 billion, and much of it has gone towards the production and procurement of crucial medical supplies. (The breakdown is visualized above; some of the funding, including today’s commitment, comes in the form of new direct grants; another tranche is repurposed funding from elsewhere in our budget, while still more is not direct funding at all; it’s in the form of loans and other financing measures. You can read more about our sources of funding here).

It’s also important to point out that there is not a hard break between the scientific phase of the fighting the pandemic and this new, more logistical one. In 2021, R&D funding will still be needed for new drugs, vaccines, and tests, in part because some of these initial ones aren’t ideally suited for low-income nations. The Pfizer vaccine, for instance, needs to be kept at sub-zero temperatures, which will be very difficult when transporting it to very rural areas. Our foundation will keep funding innovation.